ALGN vs. GILD: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALGN and GILD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
GILD’s market capitalization of 139.01 billion USD is significantly greater than ALGN’s 14.27 billion USD, highlighting its more substantial market valuation.
ALGN’s beta of 1.64 points to significantly higher volatility compared to GILD (beta: 0.31), suggesting ALGN has greater potential for both gains and losses relative to market movements.
| Symbol | ALGN | GILD |
|---|---|---|
| Company Name | Align Technology, Inc. | Gilead Sciences, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Drug Manufacturers - General |
| CEO | Joseph M. Hogan | Daniel P. O'Day |
| Price | 196.82 USD | 111.75 USD |
| Market Cap | 14.27 billion USD | 139.01 billion USD |
| Beta | 1.64 | 0.31 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | January 30, 2001 | January 22, 1992 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ALGN and GILD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALGN
10.67%
Medical - Devices Industry
- Max
- 49.04%
- Q3
- 9.53%
- Median
- -7.46%
- Q1
- -32.83%
- Min
- -82.64%
In the upper quartile for the Medical - Devices industry, ALGN’s Return on Equity of 10.67% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
GILD
31.71%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
GILD’s Return on Equity of 31.71% is on par with the norm for the Drug Manufacturers - General industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
ALGN
9.78%
Medical - Devices Industry
- Max
- 21.88%
- Q3
- 6.63%
- Median
- -1.11%
- Q1
- -21.08%
- Min
- -51.95%
In the upper quartile for the Medical - Devices industry, ALGN’s Return on Invested Capital of 9.78% signifies a highly effective use of its capital to generate profits when compared to its peers.
GILD
15.32%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
GILD’s Return on Invested Capital of 15.32% is in line with the norm for the Drug Manufacturers - General industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
ALGN
10.29%
Medical - Devices Industry
- Max
- 44.80%
- Q3
- 9.77%
- Median
- -5.53%
- Q1
- -29.37%
- Min
- -87.68%
A Net Profit Margin of 10.29% places ALGN in the upper quartile for the Medical - Devices industry, signifying strong profitability and more effective cost management than most of its peers.
GILD
20.76%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
GILD’s Net Profit Margin of 20.76% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
ALGN
14.69%
Medical - Devices Industry
- Max
- 30.13%
- Q3
- 13.12%
- Median
- 3.47%
- Q1
- -24.42%
- Min
- -80.56%
An Operating Profit Margin of 14.69% places ALGN in the upper quartile for the Medical - Devices industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
GILD
28.61%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
GILD’s Operating Profit Margin of 28.61% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ALGN | GILD |
|---|---|---|
| Return on Equity (TTM) | 10.67% | 31.71% |
| Return on Assets (TTM) | 6.71% | 10.57% |
| Return on Invested Capital (TTM) | 9.78% | 15.32% |
| Net Profit Margin (TTM) | 10.29% | 20.76% |
| Operating Profit Margin (TTM) | 14.69% | 28.61% |
| Gross Profit Margin (TTM) | 69.87% | 78.29% |
Financial Strength
Current Ratio
ALGN
1.21
Medical - Devices Industry
- Max
- 12.68
- Q3
- 6.30
- Median
- 4.05
- Q1
- 1.85
- Min
- 0.01
ALGN’s Current Ratio of 1.21 falls into the lower quartile for the Medical - Devices industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
GILD
1.37
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
GILD’s Current Ratio of 1.37 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ALGN
0.03
Medical - Devices Industry
- Max
- 2.34
- Q3
- 1.09
- Median
- 0.37
- Q1
- 0.08
- Min
- 0.00
Falling into the lower quartile for the Medical - Devices industry, ALGN’s Debt-to-Equity Ratio of 0.03 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
GILD
1.30
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
GILD’s Debt-to-Equity Ratio of 1.30 is typical for the Drug Manufacturers - General industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ALGN
--
Medical - Devices Industry
- Max
- 18.18
- Q3
- 7.53
- Median
- 0.85
- Q1
- -9.80
- Min
- -33.94
Interest Coverage Ratio data for ALGN is currently unavailable.
GILD
8.35
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
GILD’s Interest Coverage Ratio of 8.35 is positioned comfortably within the norm for the Drug Manufacturers - General industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ALGN | GILD |
|---|---|---|
| Current Ratio (TTM) | 1.21 | 1.37 |
| Quick Ratio (TTM) | 1.08 | 1.23 |
| Debt-to-Equity Ratio (TTM) | 0.03 | 1.30 |
| Debt-to-Asset Ratio (TTM) | 0.02 | 0.44 |
| Net Debt-to-EBITDA Ratio (TTM) | -0.94 | 1.61 |
| Interest Coverage Ratio (TTM) | -- | 8.35 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALGN and GILD. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALGN
0.00%
Medical - Devices Industry
- Max
- 3.57%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
GILD
2.79%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
GILD’s Dividend Yield of 2.79% is consistent with its peers in the Drug Manufacturers - General industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio
ALGN
0.00%
Medical - Devices Industry
- Max
- 102.12%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
GILD
66.02%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
GILD’s Dividend Payout Ratio of 66.02% is within the typical range for the Drug Manufacturers - General industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | ALGN | GILD |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.79% |
| Dividend Payout Ratio (TTM) | 0.00% | 66.02% |
Valuation
Price-to-Earnings Ratio
ALGN
35.35
Medical - Devices Industry
- Max
- 90.56
- Q3
- 56.92
- Median
- 43.19
- Q1
- 21.79
- Min
- 5.55
ALGN’s P/E Ratio of 35.35 is within the middle range for the Medical - Devices industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
GILD
23.34
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
GILD’s P/E Ratio of 23.34 is within the middle range for the Drug Manufacturers - General industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ALGN
3.34
Medical - Devices Industry
- Max
- 6.56
- Q3
- 3.52
- Median
- 2.22
- Q1
- 0.55
- Min
- 0.03
ALGN’s Forward PEG Ratio of 3.34 is within the middle range of its peers in the Medical - Devices industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
GILD
3.10
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
GILD’s Forward PEG Ratio of 3.10 is exceptionally high for the Drug Manufacturers - General industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.
Price-to-Sales Ratio
ALGN
3.58
Medical - Devices Industry
- Max
- 15.74
- Q3
- 8.12
- Median
- 3.40
- Q1
- 2.37
- Min
- 0.42
ALGN’s P/S Ratio of 3.58 aligns with the market consensus for the Medical - Devices industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
GILD
4.84
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
GILD’s P/S Ratio of 4.84 is in the upper echelon for the Drug Manufacturers - General industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio
ALGN
3.82
Medical - Devices Industry
- Max
- 16.65
- Q3
- 8.03
- Median
- 3.73
- Q1
- 1.92
- Min
- 0.65
ALGN’s P/B Ratio of 3.82 is within the conventional range for the Medical - Devices industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
GILD
7.27
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
Valuation at a Glance
| Symbol | ALGN | GILD |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 35.35 | 23.34 |
| Forward PEG Ratio (TTM) | 3.34 | 3.10 |
| Price-to-Sales Ratio (P/S, TTM) | 3.58 | 4.84 |
| Price-to-Book Ratio (P/B, TTM) | 3.82 | 7.27 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.62 | 14.12 |
| EV-to-EBITDA (TTM) | 16.80 | 14.75 |
| EV-to-Sales (TTM) | 3.39 | 5.43 |